# Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

> **NCT06398873** · — · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps
- Chronic Rhinosinusitis Without Nasal Polyps

## Interventions

- **DRUG:** Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

## Key facts

- **NCT ID:** NCT06398873
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-06
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398873, "Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT06398873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*